What sequence features separate thymosin beta-4 from TB-500 fragment 17-23?
Mature human thymosin beta-4 is a 43-residue member of the beta-thymosin family and is characteristically blocked by N-terminal acetylation (PMID:17468232). For identity work the one-letter sequence is Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES, numbered from the acetylated serine. Residues 17-22 are Leu-Lys-Lys-Thr-Glu-Thr, the short motif located by sequence numbering in the structural literature (PMID:12852258; PMID:17495248). Residue 23 is glutamine, so the segment named fragment 17-23 is LKKTETQ, not the hexapeptide alone. A lot sold under that fragment name should state whether the N-terminus is acetylated. Ac-LKKTETQ is the usual synthetic target when the fragment is prepared to mirror the blocked parent chain. The free-amine heptapeptide is a different molecule: it is 42 Da lighter and it fails an identity test written for the acetylated mass. The 43-mer is not a concentrated or truncated-in-name-only version of the fragment. Residues 1-16, SDKPDMAEIEKFDKSK, and residues 24-43, EKNPLPSKETIEQEKQAGES, are absent from fragment 17-23. Those missing stretches include the only methionine, at position 6, and the only phenylalanine, at position 12. Their absence changes oxidation chemistry, 280 nm response and the product-ion map. A vial labelled thymosin beta-4 that contains only Ac-LKKTETQ is a misidentified short peptide. A vial labelled TB-500 that contains the 43-mer is a different material from a vial labelled TB-500 that contains the heptapeptide. Trade names do not resolve that collision. Sequence text on the certificate should be complete, including the acetyl prefix, rather than abbreviated to a catalogue title. Structural work describes free beta-thymosin as largely disordered in solution, which is recorded here as a structural observation rather than a release specification (PMID:27450728; PMID:17495248). That description explains the scientific origin of the motif name. It is not an acceptance criterion for a research lot. Acceptance is chemical: declared sequence, declared terminal modification, and measured mass agreeing with the mass calculated for that exact structure. Where two suppliers use TB-500 for opposite structures, the written sequence is the specification, and the mass result is the check. A receiving file should therefore store the full one-letter string, not a truncated motif, so a later comparison can test whether residues outside 17-23 were present in the analysed material.
How do intact mass and charge-state envelopes distinguish the two specifications?
Intact mass separates these specifications immediately, because the structures are not close in molecular mass. Summing residue masses for LKKTETQ, adding the terminal water equivalent and adding 42.01 Da for N-acetylation gives a monoisotopic neutral mass of 888.49 Da for Ac-LKKTETQ. The corresponding average mass is approximately 889 Da. Acetylated thymosin beta-4 is the 43-residue chain, with an average molecular mass of approximately 4963.5 Da. A gap of about four kilodaltons is not a salt-form effect, a moisture effect or a routine calibration drift. If a catalogue mass is near 889 Da, the material belongs to the fragment class. If it is near 4.96 kDa, it belongs to the full-length class. Any other dominant mass should be treated as a different peptide or a transcription error until it is explained. Electrospray ionisation shows the same distinction in the charge-state envelope. Ac-LKKTETQ is typically observed as the singly and doubly protonated ions, near m/z 889.5 and m/z 445.3 on a monoisotopic scale. The 43-mer has many more lysine side chains and is ordinarily observed as a ladder of higher charge states rather than as a dominant singly charged ion near m/z 890. A spectrum that contains only the low-mass ion cannot support a 43-residue assignment, regardless of the name printed on the chromatogram. Conversely, a deconvoluted mass near 4963 Da cannot be reported as Ac-LKKTETQ. The certificate should state observed mass, theoretical mass, mass error in parts per million or daltons, charge state and whether the value is monoisotopic or average. A unit-resolution instrument can still separate 889 Da from 4963 Da. It is a weaker tool for confirming acetylation of the 43-mer against a closely related unmodified chain if the calibration bracket is poor. For the heptapeptide, loss of the acetyl group is a 42 Da shift and is within the reach of a benchtop confirmation, provided the theoretical mass on the document is the acetylated mass and not the free-amine mass. Laboratories should calculate the expected mass from the sequence on the certificate rather than copying a molecular-weight field from a product title. That calculation is the reference against which the spectrum is judged.
How does reversed-phase HPLC separate thymosin beta-4 vs TB-500?
Reversed-phase HPLC separates analytes by hydrophobic retention under a stated method. It does not identify a peptide from a trade name. Thymosin beta-4 vs TB-500 fragment 17-23 is analytically favourable because chain length and hydrophobic content differ. Ac-LKKTETQ contains one leucine and no aromatic residue. The 43-mer contains that leucine plus further hydrophobic surface, including phenylalanine at position 12. On a water-acetonitrile gradient with about 0.1% trifluoroacetic acid, the acetylated heptapeptide is expected to elute earlier than acetylated thymosin beta-4 on C18 or C8 silica. That order is a method expectation, not a universal retention time. A retention time without column, temperature, flow rate and gradient timetable is not an identity criterion. A written method should record column chemistry and dimensions, particle size, temperature, mobile phases, gradient, flow, injection volume, detection wavelength and the retention-time window set with a matched reference. If a laboratory handles both materials, system suitability should include a mixture of the two references so resolution is demonstrated rather than assumed. Spectral contrast is limited: the heptapeptide has essentially no 280 nm chromophore, and the 43-mer has phenylalanine but no tyrosine or tryptophan. A trace recorded only at 280 nm can under-detect Ac-LKKTETQ and inflate the relative area of any aromatic contaminant. Detection near 214 nm, or a dual-channel 214 nm and 280 nm record, is the more defensible purity chromatogram for either lot. Area percent is not content. A main-peak result of 98% at 214 nm means that 98% of the integrated response above the reporting threshold was assigned to that peak. It does not state milligrams of peptide in the vial, and it does not reveal a co-eluting species the gradient failed to resolve. Sample name, vial identifier and certificate header must agree. A purity number generated on a full-length method and pasted onto a fragment certificate is a documentation defect even when both figures look high. Ion-pair choice changes retention and mass-spectrometric compatibility. Trifluoroacetic acid often gives narrower peaks for these basic sequences and suppresses electrospray response. Formic acid is commonly chosen when the same peak must be confirmed by mass spectrometry. Those purity figures are not numerically interchangeable, so the certificate should name the ion-pair reagent.
Which related substances and counter-ion results belong on each certificate?
Impurity risk follows sequence, so the two materials do not share a related-substance list. Acetylated thymosin beta-4 contains methionine at position 6. Methionine sulphoxide is a +16 Da modification that reversed-phase HPLC can often resolve and that mass spectrometry can assign. Fragment 17-23 contains no methionine. A +16 Da species in an Ac-LKKTETQ lot is not methionine sulphoxide of that sequence and needs a separate explanation. The 43-mer also contains asparagine, glutamine and aspartate, so deamidation and aspartimide-related species belong in a full-length impurity review. Those pathways are not available in the same form on a heptapeptide that lacks aspartate and has glutamine only at the C-terminus. Deletion profiles differ for the same reason. Synthesis of a 43-mer can leave truncations and deletions close in mass to the parent, which may need a long gradient and a mass assignment before they are named. Synthesis of the heptapeptide produces a smaller set, such as des-Leu or des-Lys peptides, readily separated in mass from 888.49 Da. Incomplete N-acetylation matters for both if the specification is the acetylated form: the free amine is 42 Da lighter. A single 214 nm chromatogram does not prove the absence of stereoisomers. Racemisation control sits in the process record or in a chiral method, not in an area-percent figure alone. Counter-ion and water complete the comparison of what a milligram of powder contains. Both sequences are lysine-rich and are commonly isolated as trifluoroacetate or acetate salts. Salt form does not change sequence, but it changes net peptide content. Content by amino-acid analysis, or an equivalent approach, corrected for counter-ion and water, is the figure to read when lots are compared per milligram of powder. Residual trifluoroacetate may be estimated by ion chromatography or fluorine nuclear magnetic resonance, and water by Karl Fischer titration. Those rows should be separate from HPLC area percent. Identity remains the sequence-plus-mass result; content and related substances describe the lot once identity is fixed.
How should an Australian laboratory document a thymosin beta-4 or TB-500 research lot?
Australian procurement adds traceability. It does not change the chemistry. The lot file should tie the order to a batch number, the certificate, the chromatogram and the mass result. A consignment or chain-of-custody identifier may be filed against the lot. Logistics records do not replace a sequence check. Confirm that the sequence on the certificate is the sequence that was ordered. The identity block should use a chemical description, not only the name TB-500: acetylated thymosin beta-4, 43 residues, or Ac-LKKTETQ, fragment 17-23. Include the one-letter sequence, theoretical and observed masses, mass error and instrument class. The purity block should name the method, wavelength, main-peak area percent, reporting threshold and related substances by relative retention time. The content block should separate gross filled mass from net peptide content, counter-ion and water. Analysis date and agreement of sample name with the vial label close the record. If an order says only TB-500, add one of the two chemical descriptions. Accepting goods against the trade name alone is how the 43-mer and the heptapeptide become substituted. A sequence change under an unchanged item code is a change of material and should be visible in the certificate header. Regulatory status is a separate record. These materials are not for human use. A trade name does not state the current TGA position. Keep the research-use statement with the lot file and check the current scheduling instrument. A mass match and a custody record do not change that framing. The task is to know which molecule was received and to show how that was measured. Concordance is checked by placing the declared one-letter sequence, the mass calculated from that sequence, the observed mass, the chromatogram sample name and the vial identifier against one batch number. A mismatch in any of those fields is an identity discrepancy, not a labelling preference.
Frequently asked questions
Is TB-500 the same peptide as thymosin beta-4?
Not necessarily. In research catalogues, TB-500 is used both for acetylated thymosin beta-4, a 43-residue chain of about 4963.5 Da, and for fragment 17-23, commonly Ac-LKKTETQ at about 889 Da. The names match only when the certificate states the same sequence, the same terminal acetylation and a mass that agrees with that structure. A shared trade name is not an identity result.
What intact mass confirms fragment 17-23?
For the acetylated heptapeptide Ac-LKKTETQ, the monoisotopic neutral mass calculates to 888.49 Da, and the average mass is about 889 Da. Positive-ion electrospray commonly shows the singly charged ion near m/z 889.5 and the doubly charged ion near m/z 445.3. A dominant mass near 4963 Da is full-length thymosin beta-4, not the fragment. The certificate should state whether the reported mass is monoisotopic or average, and whether the N-terminus is acetylated.
Why is 214 nm preferred to 280 nm for these lots?
Fragment 17-23 has no aromatic residue, so 280 nm absorbance is negligible. Full-length thymosin beta-4 has phenylalanine but no tyrosine or tryptophan, so 280 nm response is weak. A 280 nm trace can miss the heptapeptide and distort area percent if an aromatic contaminant is present. Peptide-bond detection near 214 nm, ideally with a second channel at 280 nm, is the more reliable purity record for both specifications.
Can area-percent purity prove which peptide was supplied?
No. Area percent describes the share of integrated detector response assigned to the main peak under a stated method. It does not identify the sequence, and it does not equal net peptide content. The same numerical purity can be reported for either molecule if each lot is clean. Identity requires the declared sequence plus an observed mass that matches the calculated mass. Content requires a separate counter-ion and water correction.
What should be checked on an Australian research-lot file?
Check concordance of order, vial label, certificate header and chromatogram sample name. Confirm the chemical description is either the acetylated 43-mer or Ac-LKKTETQ, not the trade name alone. File the method identifier, 214 nm area percent, related-substance table, observed mass and mass error with the batch number. Read net peptide content separately from gross fill. Keep the research-use statement with the lot. A shipping or custody record supports traceability; it does not replace those analytical fields.
References
- PMID:12852258 — Thymosin beta 4 interactions — Vitam Horm — 2003
- PMID:17468232 — beta-Thymosins — Ann N Y Acad Sci — 2007
- PMID:17495248 — The beta-thymosin enigma — Ann N Y Acad Sci — 2007
- PMID:27450728 — Structures of Thymosin Proteins — Vitam Horm — 2016
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
